Swiger Joins ImpeDx Diagnostics to Lead R&D

October 2017

ImpeDx Diagnostics is pleased to announce the addition of Dr. Roy R Swiger as a senior member of our management team.   Roy joins the company as Senior Vice-President of Research and Development and brings vast experience in the life sciences industry to our team.   He is a veteran of DOE’s Genome Program (Livermore, CA), MRI Global (Kansas City, MO), and a handful of startups.  Founder and CEO Steve O’Connor said, “We are excited to have Roy on our team, he has the experience we need as we charge toward developing our platform.”



Overland Park, KS – ImpeDx Diagnostics (a privately held company) is developing a multiplexed phenotypic diagnostic system to perform extremely rapid Antibiotic Susceptibility Testing (AST) on a variety of different patient sample types (blood, urine, sputum, etc.) that will allow clinicians to provide targeted, effective antibiotics to patients in hours, rather than days or weeks as with currently available products.   Our system compliments existing rapid pathogen identification systems already on the market and provides the full answer clinicians require in order to implement appropriate patient care, improving patient outcomes while substantially reducing healthcare costs and the fostering of antibiotic resistance.  For more information, visit www.impedx.com.


ImpeDx Diagnostics

Dr. Steve O’Connor, CEO

(626) 893-2514